Drug intelligence / Profile preview

(2S)-2-[(2,1,3-benzothiadiazol-4-ylsulfonyl)amino]-2-phenyl-N-pyridin-4-ylacetamide

Development stage: Unknown
Modality: Small Molecules

Overview

This compound is a synthetic small molecule belonging to the class of alpha amino acid amides. Its structure features a benzothiadiazole sulfonamide moiety linked to a phenyl and pyridinylic acetamide group. It is listed as an experimental compound in DrugBank with no approved therapeutic indications or known clinical use. The precise mechanism of action and biological targets are not described in public databases. It has been studied primarily as a chemical entity rather than as an active pharmaceutical ingredient[1].

Other names: (2S)-2-(2,1,3-benzothiadiazole-4-sulfonamido)-2-phenyl-N-(pyridin-4-yl)acetamide

Targets

Cyp (Cyclophilin family)

Beyond the preview

Go deeper on (2S)-2-[(2,1,3-benzothiadiazol-4-ylsulfonyl)amino]-2-phenyl-N-pyridin-4-ylacetamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on (2S)-2-[(2,1,3-benzothiadiazol-4-ylsulfonyl)amino]-2-phenyl-N-pyridin-4-ylacetamide.

Explore the full profile